Introduction
============

The technological advances made in the twenty and twenty-first centuries gave rise to the most prosperous society which has ever existed ([@B21]). This well-being is associated with an overall drastic increase in the average life expectancy ([@B57]) and with several problems faced by the today's society. One of these problems is a result of the increase in caloric uptake and lack of exercise which results in an epidemic of overweight. Obese people present major challenges, as obesity entails a myriad of risk factors for chronic diseases like diabetes, heart diseases and even some cancers ([@B19]). Furthermore, the extended life span associated with environmental factors such as tobacco smoking, industrialization and urbanization are causes behind the increase in cancer incidence rates ([@B62]). Antibiotic resistance is another emerging problem. Overabundance in the use of antibiotics as well as their intense misuse resulted in the phenomenon of antibiotic resistance, which is rapidly occurring worldwide, with many commonly used antibiotics having already been rendered useless ([@B58]). Several are thus the challenges at the beginning of the twenty-first century.

In recent years, research into new compounds has been focused in the ocean and many marine organisms are proving to be good sources of interesting new leads ([@B20]) Drugs like xestospongin C and several manoalides were discovered in marine animals like sponges ([@B39]; [@B52]). Sponges have a diverse microbiological community, often showing the presence of archaea, fungi, microalgae and a great diversity of bacterial phyla ([@B54]). While sponges are good candidates for drug discovery, a major setback is that sponges may only contain minute quantities of these compounds in their body, which may invalidate clinical trials ([@B35]). However, it seems that the symbiotic microbiological community is the true origin of several relevant compounds ([@B61]). It is also known that *Actinobacteria* are copious producers of bioactive metabolites. Particularly prolific are species isolated from soil and affiliated to the *Actinomycetales*, most notably the genus *Streptomyces* ([@B37]). Less studied are marine *Actinobacteria* which have nonetheless already shown potential as sources for novel leads. Several bioactive molecules, ranging from antimalarians like salinipostins, cytotoxics such as marinomycins to antibacterials as abyssomicins, have all been isolated from *Actinobacteria* found in marine environments ([@B5]; [@B28]; [@B49]; [@B11]).

This study aimed to contribute to the need of finding new and more effective bioactive molecules against several of the earlier mentioned threats faced by human kind nowadays. For this, eighteen species from the *Actinomycetales* previously isolated from *Erylus* spp. sponges collected in Portuguese marine waters (Açores, Madeira, and continental shelf) were screened for antimicrobial, anti-cancer, anti-parasitic and anti-obesogenic activities.

Materials and Methods {#s1}
=====================

Biological Material
-------------------

The bacteria under study belong to the order *Actinomycetales* within the phylum *Actinobacteria* and were isolated from marine sponges of the genus *Erylus, E. discophorus* (Berg01 and Berg02, from the continental shelf at Berlengas, Portugal) and *E. deficiens* (\#91, from the continental shelf at Gorringe, Portugal) and *E. mamillaris* (SM, Açores, Portugal) ([Table 1](#T1){ref-type="table"}). Most of these strains showed the presence of interesting secondary metabolism genes and/or bioactivities in previous antimicrobial screenings ([Table 1](#T1){ref-type="table"}; [@B16], [@B17]).

###### 

List of *Actinomycetales* used in this study evidencing their physiological affiliation and bioactive potential.

  Strain ID        Affiliation                                                          Secondary metabolism gene   Previous bioactivity
  ---------------- -------------------------------------------------------------------- --------------------------- ----------------------
  \#91_17^∗^       *Dermacoccus* sp. Ellin185; AF409027                                 NRPS                        CA
  \#91_20          *Rhodococcus hoagii* CUB1156; AJ272469                               N/D                         NA
  \#91_29^∗^       *Microbacterium foliorum* BJC15-C14; JX464206                        N/D                         CA
  \#91_31^∗^       *Microbacterium hydrocarbonoxydans* 3084; EU714352                   N/D                         CA
  \#91_34^∗^       *Microbacterium esteraromaticum* 2122; EU714337                      N/D                         CA
  \#91_35^∗^       *Microbacterium phyllosphaerae (T)*; DSM 13468; P 369/06; AJ277840   PKS-I                       CA; VA
  \#91_36.1^∗^     *Rhodococcus equi* type strain*:* DSM20307; X80614                   PKS-I; NRPS                 CA; VA; EC
  \#91_37^∗^       *Microbacterium foliorum* BJC15-C1; JX401513                         N/D                         CA; VA
  \#91_40^∗^       *Microbacterium foliorum* BJC15-C14; JX464206                        PKS-I                       CA; VA
  \#91_44          *Rhodococcus* sp.                                                    PKS-I; NRPS                 NA
  \#91_54          *Rhodococcus qingshengii* KUDC1814; KC355321                         NRPS                        CA, VA
  SM 115           *Agrococcus baldri* B-G-NA10                                         PKS-I                       NA
  SM 116           *Agrococcus baldri* B-G-NA10                                         PKS-I                       NA
  Berg01-119c      *Microbacterium sp.* ZJY-409                                         N/D                         VA; VF
  Berg02-22.2^∗^   *Gordonia sp.* DEOB200; AY927227                                     PKS-I                       BS
  Berg02-26        *Micrococcus luteus;* KCL-1; DQ538135                                N/D                         NA
  Berg02-78^∗^     *Gordonia terrae* 3269aBRRJ; FJ200386                                PKS-I; NRPS                 BS
  Berg02-79^∗^     *Microbacterium sp.* M63-2; EF061897                                 N/D                         BS
                                                                                                                    

∗

Strains assayed for anti-obesity; PKS-I, Polyketide Synthase I; NRPS, Non-ribosomal Peptide Synthetases; N/D, Not determined; NA, No Activity; CA, Candida albicans; BS, Bacillus subtilis; EC, Escherichia coli; VA, Vibrio anguillarum; VF, Vibrio fisheri

.

For the antimicrobial assays six different pathogens were tested, *Escherichia coli* ATCC25922 (EcoWT), *Klebsiella pneumoniae* ATCC 700603, Methicillin-resistant *Staphylococcus aureus* MB5393 (MRSA), *Staphylococcus aureus* ATCC29213 (MSSA), *Acinetobacter. baumannii* MB5973 *Aspergillus fumigatus* ATCC46645, and *Candida albicans* ATCC64124. For the anti-cancer assays the following cell lines were tested: human melanoma (A2058), human lung carcinoma (A549), human hepatocellular carcinoma (HepG2), human colon cancer (HT29), human breast cancer (MCF7), and human pancreatic cancer (MIA PaCa-2). Anti-parasitic activity was assessed using the parasite *Trypanosoma cruzi* Tulahuen C4 strain. As *T. cruzi* is an obligate intracellular parasite, it was cultivated inside host L6 rat skeletal muscle cells. Anti-obesogenic activity was tested using the zebrafish (*Danio rerio*) larvae.

Growth Media
------------

The various *Actinomycetales* were cultivated and maintained in Marine Agar (MA) medium ([@B16], [@B17]) at 25°C in darkness.

To conduct the screenings, liquid fermentations of the strains were prepared, using ten different culturing media. These different media provide a range of nutritional conditions (from oligotrophic to heterotrophic status) aiming to favor the production of bioactive metabolites. These include several ready prepared media such as Antibiotic Broth (AB) (1.0 g/L dextrose, 3.68 g/L K~2~HPO~4~, 1.5 g/L meat extract, 5.0 g/L peptone, 1.32 g/L KH~2~PO~4~, 3.5 g/L NaCl and 1.5 g/L yeast extract), Tryptic Soy Broth (TSB) (17 g/L tryptone, 3 g/L phytone, 5 g/L NaCl, 2.5 g/L K~2~HPO~4~ and 2.5 g/L glucose) and Marine Broth (MB) (5 g/L peptone, 1 g/L yeast extract, 40 g/L sea salts) CGY ([@B46]), DEF-15 ([@B29]), IN-CRY ([@B42]), R358 ([@B24]), and other media specified in [Table 2](#T2){ref-type="table"}. Moreover, as all the strains were previously isolated from a marine environment, Sea salts (Sigma-Aldrich) were added to all the media at a concentration of 30 g/L, except in the medium MB.

###### 

Composition of the media used for liquid culture extractions.

  Reagents (g/L)       Medium                          
  -------------------- --------------- --------------- ---------------
  Yeast Extract        --              1.0             5.0^∗^ 10^-1^
  Casein hydrolysate   --              --              5.0^∗^ 10^-1^
  Glucose              10              10              5.0^∗^ 10^-1^
  Fructose             20              --              --
  Maltose              10              10              --
  Peptone              5               --              5.0^∗^ 10^-1^
  Amicase              5               --              --
  Starch               --              10              5.0^∗^ 10^-1^
  Soytone              --              5.0             --
  Tryptone             --              4.0             --
  K~2~HPO~4~           --              2.0^∗^ 10^-1^   3.0^∗^ 10^-1^
  NaCl                 --              2.0^∗^ 10^-2^   --
  KCl                  --              2.0^∗^ 10^-5^   --
  MgSO~4~.7H~2~O       --              5.0^∗^ 10^-2^   4.0^∗^ 10^-2^
  KH~2~PO~4~           --              1.0^∗^ 10^-1^   --
  CaCl~2~.H~2~O        --              5.0^∗^ 10^-2^   --
  C~3~H~3~NaO~3~       --              --              3.0^∗^ 10^-1^
  FeSO~4~.7H~2~O       5.0^∗^ 10^-4^   --              --
  ZnCl~2~              --              2.0^∗^ 10^-5^   --
  ZnSO~4~.7H~2~O       5.0^∗^ 10^-4^   --              --
  MnSO~4~.H~2~O        1.0^∗^ 10^-4^   1.0^∗^ 10^-4^   --
  CuSO~4~.5H~2~O       5.0^∗^ 10^-5^   --              --
  CoCl~2~.6H~2~O       5.0^∗^ 10^-5^   2.0^∗^ 10^-5^   --
  SnCl~2~.2H~2~O       --              5.0^∗^10^-6^    --
  H~3~BO~3~            --              1.0^∗^ 10^-5^   --
  Na~2~MoO~4.~2H~2~O   --              1.2^∗^ 10^-5^   --
  CuSO~4~              --              1.5^∗^ 10^-5^   --
  FeCl~3~              --              5.8^∗^ 10^-3^   --
                                                       

Extraction Protocols
--------------------

### Small Scale-Culture Extraction

A first small-scale fermentation in 0.8 mL cultures was performed. Bacterial strains were grown in the 10 media in 96-well plates (Duetz system ^[1](#fn01){ref-type="fn"}^) ([@B14]; [@B38]; [@B13]; [@B43]; [@B44]) for 5 days at 25°C, 20% humidity and 300 revolutions per minute (rpm). After incubation, 0.8 mL acetone were added to each bacterial culture. The acetone/culture mixture was mixed for 1 h at 170 rpm and later evaporated up to a final volume of 0.6 mL in a Genevac^®^ centrifugal evaporator. Due to a large presence of salts that might influence subsequent assays, the 0.6 mL were captured in a Waters^TM^ Oasis^®^ HLB extraction plates, with the sorbent Oasis^®^ HLB. The Oasis^®^ HLB plate was equilibrated using first methanol and after HPLC grade water. The extract was run though the Oasis^®^ HLB plate in 0.2 mL steps, vacuum-eluted and the collected volume discarded. Subsequently, the secondary metabolites were captured with methanol. The methanol was, then removed in a Genevac^®^ and the recovered metabolites were dissolved in 0.4 mL 20% DMSO. This allowed a twofold concentration increase of the extracts. Additionally, as controls, culture media were also extracted with the same protocol.

### Medium-Scale Culture Extraction

Bacteria that showed bioactive extracts were re-fermented in higher volumes (EPA vials system -- 40 mL). Ten milliliters of bacterial cultures were grown for 5 days at 25°C with 20% humidity and 220 rpm. After the 5 days period, 10 mL acetone were added (1:1) to each culture and mixed for 1 h. The acetone/culture mixture was then evaporated under nitrogen to 9 milliliters to remove all traces of acetone. To remove the salt contamination, the resin SEPABEADS^®^ SP207ss was used. Two milliliters of a ready prepared suspension of SP207ss were added to the culture and mixed for 1 h. The vials were then centrifuged, and the supernatant discarded. The resin was washed with HPLC water. Ten mL of acetone were added to the resin, centrifuged and the acetone was collected, evaporated under nitrogen and dissolved in 2 mL of 20% DMSO. A fivefold increase of the extracts was achieved. As controls, media samples were also extracted with the same protocol.

### Anti-obesogenic Assays Culture Extraction

To test possible anti-obesity compounds produced by the selected strains, each strain was grown in 100 mL Marine Broth at 25°C, 200 rpm for 5 days. For the extraction, cell pellets were lyophilized and mixed twice for 30 min with 50 mL methanol. The collected methanol was dried in a rotatory evaporator and the weight of the extract measured. The extracts were stored at -20°C and, when needed, dissolved in 100% DMSO at a concentration of 10 mg/mL.

Bioactivity Assays
------------------

### Antimicrobial Assays

Previously described methods using pathogenic microorganisms from Fundación MEDINA's collection were performed to test for antibacterial and antifungal properties ([@B40]; [@B3]). Briefly, single colonies of each microorganism were incubated overnight at 37°C and 220 rpm in their corresponding medium and then diluted in order to obtain assay inoculum of approximately 1.1 × 10^6^ CFU/mL for methicillin-resistant *S. aureus* MB 5393, 5.0 × 10^5^ CFU/mL for *A. baumannii* MB5973, *E. coli* ATCC 25922, *K. pneumoniae* ATCC 700603 and *S. aureus* ATCC 29213 and 2.5 × 10^4^ CFU/mL for *A. fumigatus* ATCC46645. For *C. albicans*, the OD at 660 nm of the liquid culture was adjusted to 0.25 and diluted 1:100 for assay inoculum.

For all the assays 90 μL/well of the corresponding diluted inoculum were mixed with 10 μL/well of extract. Positive and negative internal plate controls were included following the previously described methodologies. Absorbance or fluorescence were measured with an Envision plate reader. Genedata Screener software (Genedata, Inc., Basel, Switzerland) was used to analyze the data and to calculate the percentage of growth inhibition of the extracts and the RZ' factor to estimate the robustness of the assays ([@B64]). In all experiments performed in this work, the RZ' factor obtained was between 0.87 and 0.92.

### Anti-cancer Assays

The cytotoxic bioactivity of the extracts was tested by using the portfolio of HTS assays from MEDINA according to [@B9]. Cytotoxic activity of the extracts (5 μL in 19 μL medium) was tested against human hepatocellular carcinoma (HepG2) for Duetz extracts and against human melanoma (A2058), human lung carcinoma (A549), human hepatocellular carcinoma (HepG2), human colon cancer (HT29), human breast cancer (MCF7), and human pancreatic cancer (MIA PaCa-2) for EPA vials extracts.

### Anti-parasitic Assays

Anti-parasitic bioactivity of the extracts (5 μL of 1:1500 dilution) was tested against *T. cruzi* Tulahuen C4 strain according to [@B2].

### Anti-obesogenic Assays

The anti-obesity activity of the extracts taken from 11 strains arbitrarily chosen ([Table 1](#T1){ref-type="table"}) was tested using zebrafish larvae as described in [@B55]. Briefly, hatched larvae were transferred to 48-well plates, 6--8 individual larvae per well, with 750 μL water and N-phenylthiourea. Larvae were then treated with 10 μg/mL extracts or 0.1% DMSO or 50 μM Resveratrol for 48 h. At 24 h, the solutions in the wells were renewed and 10 ng/ml Nile red added. For imaging, the larvae were anesthetized with 0.03% tricaine, fluorescence intensity acquired in a fluorescence microscope (Leica DM6000B) and the images analyzed with the software ImageJ. Statistical significance was evaluated with an ANOVA and Dunnett's test.

### Dereplication

Dereplication of the extracts was performed by Liquid Chromatography/High-Resolution Mass Spectroscopy (LC/HRMS) which was performed in an Agilent 1200 Rapid Resolution HPLC interfaced to a Bruker maXis mass spectrometer. The column used for separation was a Zorbax SB-C8 column (2.1 × 30 mm, 3.5 mm particle size), with two solvents used for the mobile phase. Both solvents were composed of water and acetonitrile in a 90:10 ratio for solvent A and in a 10:90 ratio for B. Both solvents contained 13 mM ammonium formiate and 0.01% trifluoracetic acid. The mass spectrometer was operated in positive ESI mode. The retention time and exact mass of the components were compared against Fundación MEDINA's high resolution mass spectrometry database, and when a match was obtained it was reported as a named compound. For the components with no matches in the MEDINA database, the predicted molecular formula and exact mass were searched for in the Chapman and Hall Dictionary of Natural Products database. If a plausible match was found, considering the exact mass/molecular formula, the producing microorganism and the target assay, the molecule was reported as a suggested component of the fraction ([@B45]).

Results
=======

Small-scale extracts (0.8 mL cultures, performed in Duets plates) are useful for a rapid evaluation of the bioactive profile of the strains. However, due to the small volume of the extracts, only a limited number of assays could be performed. For this reason, only the antimicrobial and anti-parasitic assays were run with the full number of targets, while in the anti-cancer assay, only the HepG2 cell line was assayed. This cell line is used as a model system for studies of liver toxicity ([@B36]) which is an important characteristic of the drugability of any molecule.

From the 18 different strains tested in the 10 media, only 6 strains demonstrated bioactivity in one or more of the assays performed ([Table 3](#T3){ref-type="table"}). Antifungal activity against *A. fumigatus* ATCC46645 was obtained in several media with strains \#91_17, Berg02-26, Berg02-22.2, and Berg02-78. Strain Berg02-79 showed activity against the methicillin-resistant *S. aureus* (MRSA) and strains \#91_40, Berg02-22.2 Berg02-78 and Berg02-79 were effective against HepG2 cells. Berg02-78 extracts proved to be bioactive against *T. cruzi* Tulahuen C4. As extracts from strains \#91_40, Berg02-22.2, Berg02-78, and Berg02-79 in medium IN-CRY proved to be hepatotoxic, no further testing was done with these extracts.

###### 

Summary of the bioactivities obtained with the Duetz extracts.

  Strain ID     Affiliation                 Bioactivity            
  ------------- --------------------------- ------------- -------- -----
  \#91_17       *Dermacoccus* sp.           AF            CGY      66
                                                          IN-CRY   86
                                                          M016     60
  \#91_40       *Microbacterium foliorum*   HepG2         IN-CRY   66
  Berg02-22.2   *Gordonia* sp.              AF            AB       64
                                            HepG2         IN-CRY   62
  Berg02-26     *Micrococcus luteus*        AF            IN-CRY   69
                                                          R358     57
  Berg02-78     *Gordonia terrae*           AF            AB       51
                                            TC            IN-CRY   50
  Berg02-79     *Microbacterium* sp.        MRSA          R358     100
                                            HepG2         IN-CRY   56
                                                                   

AF, A. fumigatus ATCC46645; CA, C. albicans ATCC64124; MRSA, Methicillin-resistant S. aureus MB 5393; TC, T. cruzi Tulahuen C4

.

With the medium scale extracts (10 mL culture -- EPA vials) and as the volume was no longer a limitation, all microbiological, parasitic and cancer cell lines targets and assays were tested. Antifungal activity against *A. fumigatus* ATCC46645 and *C. albicans* ATCC64124 was obtained with strains \#91_17 (in media CGY and M016) and Berg02-26 (in medium IN-CRY) ([Table 4](#T4){ref-type="table"}). Regarding the anticancer assays, the extracts from AB medium of strain Berg02-22.2 showed activity against human melanoma cell line (A2058), human hepatocellular carcinoma cell line (HepG2), human colon cancer cell line (HT29), human breast cancer cell line (MCF7), and human pancreatic cancer cell line (MIA PaCa-2) ([Table 4](#T4){ref-type="table"}). No activity was observed against the human lung carcinoma cell line (A549). Furthermore, strain Berg02-22.2 also showed anti-parasitic activity against *T. cruzi* Tulahuen C4 ([Table 4](#T4){ref-type="table"}). With the medium scale extracts, the bioactivities previously detected in the small-scale extracts of strains Berg02-78 and Berg02-79 were not confirmed ([Tables 3](#T3){ref-type="table"}, [4](#T4){ref-type="table"}).

###### 

Summary of the bioactivities obtained with the EPA extracts.

  Strain ID     Affiliation            Bioactivity            
  ------------- ---------------------- ------------- -------- -----
  \#91_17       *Dermacoccus* sp.      AF            CGY      67
                                                     M016     93
                                       CA            CGY      82
                                                     M016     100
  Berg02-22.2   *Gordonia* sp.         TC            AB       91
                                       A2058         AB       71
                                       HepG2         AB       88
                                       HT29          AB       78
                                       MCF7          AB       82
                                       MIAPaCa-2     AB       72
  Berg02-26     *Micrococcus luteus*   AF            IN-CRY   58
                                       CA            IN-CRY   75
                                                              

AF, A. fumigatus ATCC46645; CA, C. albicans ATCC64124; MRSA, Methicillin-resistant S. aureus MB 5393; TC, T. cruzi Tulahuen C4.

The results of the anti-obesity activity obtained are shown in [Figure 1](#F1){ref-type="fig"}, [2](#F2){ref-type="fig"}. Larvae incubated with only DMSO, the solvent control of the experiment, showed an intense red fluorescent staining which was considered as the 100% level of lipid content ([Figure 1B](#F1){ref-type="fig"}). As DMSO has low toxicity and does not affect lipid accumulation on zebrafish larvae, as shown by [@B25], it is the commonly used solvent in the fish embryo tests ([@B26]). When larvae were treated with final concentration of 50 μM resveratrol, the positive control of the experiment, a complete absence of red fluorescent staining was visible ([Figure 1D](#F1){ref-type="fig"}, [2](#F2){ref-type="fig"}) which is indicative of reduction of lipid accumulation.

![Zebrafish larvae under brightfield **(A,C,E,G)** and fluorescence microscopy **(B,D,F,H)**. In **(A,B)** larvae were exposed only to DMSO, showing a normal lipid buildup, situated mostly among the lower abdomen; in **(C,D)** larvae were exposed to resveratrol, showing a decrease of neutral lipid staining; in **(E,F)** larvae were exposed to extract from strain \#91--40; in **(G,H)** larvae were exposed to extract from strain \#91-17. These larvae showed a visible decrease and increase in fluorescence when compared to the DMSO treated larvae, respectively. This implies that the extract altered the accumulation of lipids in treated larvae.](fmicb-10-00727-g001){#F1}

![Percentage of fluorescent staining of neutral lipids in zebrafish larvae. Values are presented as mean fluorescence intensity relative to the DMSO group in a box-whisker plot. Statistical differences are represented as asterisks, ^∗∗^*p* \< 0.01.](fmicb-10-00727-g002){#F2}

The zebrafish larvae treated with the majority of extracts did not show different fluorescence levels compared to the DMSO control. However, extracts from two strains, \#91_29 and \#91_40, reduced significantly the level of fluorescence by 47% and 50% ([Figure 1F](#F1){ref-type="fig"}, [2](#F2){ref-type="fig"}), respectively. The extract from strain \#91_17 induced a significant increase (43%) in fluorescence levels ([Figure 1H](#F1){ref-type="fig"}, [2](#F2){ref-type="fig"}). Statistical analysis showed that these results are statistically different from the control \[*F*~\[19,~ ~133\]~ = 8.97; *p* \< 0.01\].

HPLC-HRMS results showed that the extract from strain \#91_17 (antifungal activity and increase in neutral lipids) has a high complexity of already identified molecules ([Table 5](#T5){ref-type="table"}) which are several diketopiperazines and the plant hormone indole acetic acid (IAA). The four diketopiperazines identified in both the extracts from media AB and M016 were cyclo(prolyltyrosyl), cyclo(\[iso\]leucylprolyl), cyclo(phenylalanylprolyl), and cyclo(prolylvalyl). Moreover, four components with the following formulae, C~41~H~60~N~2~O~9~, C~43~H~64~N~2~O~9~, C~22~H~38~N~4~O~5~, and C~22~H~21~N~3~O~3~, were also identified in the extracts. These are not described in the Chapman and Hall Dictionary of Natural Products database.

###### 

Dereplication of the selected active extracts.

  Strain ID     Culture medium   Putatively detected components
  ------------- ---------------- --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  \#91_17       CGY              Cyclo(prolyltyrosyl), cyclo(\[iso\]leucylprolyl), cyclo(phenylalanylprolyl), cyclo(prolylvalyl), 1*H*-indole-3-acetic acid, C~41~H~60~N~2~O~9,~ and C~43~H~64~N~2~O~9~.
  \#91_17       M016             Cyclo(prolyltyrosyl), cyclo(\[iso\]leucylprolyl), cyclo(phenylalanylprolyl), cyclo(prolylvalyl), 1*H*-indole-3-acetic acid, C~22~H~38~N~4~O~5~ and C~22~H~21~N~3~O~3~
  Berg02-22.2   AB               Cyclo(\[iso\]leucylprolyl), Cyclo(phenylalanylprolyl), C~52~H~74~N~10~O~11~, C~35~H~28~N~6~O~8~, C~28~H~41~N~5~O~10~, Gly-Pro-Phe-Pro-Ile peptide, nocardichelin A, nocardichelin B and an undescribed nocardichelin (C~42~H~69~N~5~O~8~).
  Berg02-26     IN-CRY           Cyclo(\[iso\]leucylprolyl), cyclo(prolyltyrosyl) C~22~H~21~N~3~O~3~ and C~13~H~14~N~2~O~3~ (coincidence with caerulomycin G.)
                                 

In the extract from the AB medium of strain Berg02-22.2 (antifungal in Duetz and antiparasitic and anticancer activity in EPA vials), both Nocardichelin A (C~40~H~65~N~5~O~8~) and B (C~38~H~61~N~5~O~8~) were found, as well as a component with C~42~H~69~N~5~O~8~ as molecular formula and UV spectrum and ionization pattern similar to both nocardachelins, suggesting that this component is a new nocardachelin not described previously ([Figure 3](#F3){ref-type="fig"}). The peptide Gly-Pro-Phe-Pro-Ile and the diketopiperazines cyclo(\[iso\]leucylprolyl), cyclo(phenylalanylprolyl) were also detected. Furthermore, components with the formulae C~52~H~74~N~10~O~11~, C~35~H~28~N~6~O~8~, C~28~H~41~N~5~O~10~ were found to be present.

![UV and mass spectra of **(A)** nocardichelin A and **(B)** component C~42~H~69~N~5~O~8~ detected in the extract from the AB medium of strain Berg02-22.2. The comparison of the spectra shows the similarities between the two components which suggest that the component C~42~H~69~N~5~O~8~ is a new nocardichelin.](fmicb-10-00727-g003){#F3}

The extract from the IN-CRY medium of strain Berg02-26 (antifungal activity) showed the presence of two diketopiperazines and two other compounds. Compound C~22~H~21~N~3~O~3~ seems to be related to the diketopiperazine cyclo(prolyltryrosyl), as the UV spectrum is similar. Component C~13~H~14~N~2~O~3~ matches caerulomycin G in the DNP. However, the UV spectrum is also similar to cyclo(prolyltryrosyl).

Discussion
==========

The selected strains under study all belong to the *Actinomycetales*, an order that is known for the production of a great number of useful secondary metabolites ([@B34]; [@B56]; [@B4]). Although these strains do not belong to the most prolific genera, *Streptomyces* ([@B50]; [@B53]; [@B31]) or *Salinispora* ([@B23]), they hold great potential for novel pharmaceutically relevant molecules. The strains here studied were chosen based on previous molecular and screening evidences of bioactive potential ([@B16], [@B17]). As evidenced in [Table 1](#T1){ref-type="table"}, many of the strains hold key genes to produce secondary metabolites, like polyketide synthases (PKS) and non-ribosomal peptide synthetases (NRPS) and demonstrated antimicrobial bioactivity.

For an overall view of the results obtained, bioactivities and extracts dereplication results are summarized in [Table 6](#T6){ref-type="table"}.

###### 

Summarized results from the work.

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Strain        Afiliation                  Lipid assay activity   Bioctive Duetz extracts   Bioctive EPA extracts   Detected components in bioactive EPA extracts               
  ------------- --------------------------- ---------------------- ------------------------- ----------------------- ----------------------------------------------- ----------- --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  \#91_17       *Dermacoccus* sp.           -43%                   CGY\                      AF                      CGY                                             AF; CA      Cyclo(prolyltyrosyl), cyclo(\[iso\]leucylprolyl), cyclo(phenylalanylprolyl), cyclo(prolylvalyl), 1H-Indole-3-acetic acid, C41H60N2O9 and C43H64N2O9
                                                                   IN-CRY                                                                                                        

                                                                   M016                                              M016                                            AF; CA      Cyclo(prolyltyrosyl), cyclo(\[iso\]leucylprolyl), cyclo(phenylalanylprolyl), cyclo(prolylvalyl), 1H-Indole-3-acetic acid, C22H38N4O5 and C22H21N3O3

  Berg02-22.2   *Gordonia* sp.              NA                     AB                        AF                      AB                                              TC          Cyclo(\[iso\]leucylprolyl), cyclo(phenylalanylprolyl), C52H74N10O11, C35H28N6O8, C28H41N5O10, the peptide Gly-Pro-Phe-Pro-Ile, nocardichelin A, nocardichelin B and C42H69N5O8

                                                                                                                                                                     A2058       

                                                                                                                                                                     HepG2       

                                                                   IN-CRY                    HepG2                                                                   HT29        

                                                                                                                                                                     MCF7        

                                                                                                                                                                     MIAPaCa-2   

  Berg02-78     *Gordonia terrae*           NA                     AB                        AF                      N/T                                                         N/T

                                                                   IN-CRY                    TC                                                                                  

  \#91_29       *Microbacterium foliorum*   47%                    NA                                                NA                                                          N/T

  \#91_40       *Microbacterium foliorum*   50%                    IN-CRY                    HepG2                   N/T                                                         N/T

  Berg02-79     *Microbacterium* sp.        NA                     R358                      MRSA                    N/T                                                         N/T

                                                                   IN-CRY                    HepG2                                                                               

  Berg02-26     *Micrococcus luteus*        NA                     IN-CRY                    AF                      IN-CRY                                          AF          Cyclo(\[iso\]leucylprolyl), cyclo(prolyltyrosyl), C22H21N3O3 and C13H14N2O3

                                                                   R358                                                                                              CA          

                                                                                                                                                                                 
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

AF, A. fumigatus ATCC46645; CA, C. albicans ATCC64124; MRSA, Methicillin-resistant S. aureus MB 5393; TC, T. cruzi Tulahuen C4, N/T, Not tested

.

Our small-scale results not only confirmed the bioactive potential seen previously but proved that several of the selected strains possessed a variable repertoire of bioactivities ([Table 3](#T3){ref-type="table"}). In the small-scale extraction results, *Dermacoccus* sp. strain \#91_17 showed activity against *A. fumigatus* but not against *C. albicans*, as had previously been shown ([@B17]). However, with medium-scale extraction, *C. albicans* bioactivity was restored ([Table 4](#T4){ref-type="table"}). Bioactive compounds have been discovered in *Dermacoccus* genus. *Dermacoccus nishinomiyaensis* has displayed the capability to produce monensins A and B, which are produced in a classic polyketide pathway ([@B1]). Monensin has been tested as a chelating agent for the treatment of lead poisoning, with promising results in mice ([@B22]). Phenazine-type pigments, dermacozines, have been isolated from *Dermacoccus abyssi*. Dermacozines F and G have been shown to induce moderate cytotoxic against leukemia cell line K562 ([@B34]). Hence, *Dermacoccus* has shown to be a genus with a good potential biotechnological value. In this study, *Dermacoccus* sp. strain \#91_17 did not display any anti-cancer bioactivity but good anti-fungal activity against *C. albicans* and *A. fumigatus*. Dereplication of the medium-scale extracts pointed to the presence of several bioactive diketopiperazines, the plant hormone IAA and some unidentified molecules ([Table 5](#T5){ref-type="table"}). The diketopiperazine cyclo(prolyltyrosyl) in the form of (3S, 8aS) can have antibacterial and cytotoxic effects ([@B7]). Cyclo(phenylalanylprolyl) can show different configurations, with one configuration (3R, 8aS) showing some phytotoxic activity and another (3S, 8aS) showing broad antibacterial activity and gastrointestinal cell maturation enhancing activity ([@B6]). Cyclo(prolylvalyl) is an diketopiperazine antibiotic, with a wide spectrum of activity, with the form (3R, 8aR) active against *Vibrio anguillarum* and the (3S, 8aS) showing a broad antibacterial spectrum ([@B7]). In fact, *Dermacoccus* sp. strain \#91_17 demonstrated activity against *V. anguillarum* in a previous study ([@B17]).

*Gordonia* sp. Berg02-22.2 and *Gordonia terrae* Berg02-78 possess at least one PKS-I gene and showed activity against *Bacillus subtilis* in the previous studies ([@B16]). Neither *Gordonia* did show any activity against any of the Gram-positive strains tested in our study (although *B. subtilis* was not tested) but, instead, displayed activity against *A. fumigatus* ([Table 3](#T3){ref-type="table"}). However, antifungal activity of EPA extracts from Berg02-22.2 and Berg02-78 was not observed. Different culture conditions such as the ones in Duetz and EPA can influence the production of bioactive metabolites ([@B59]). Yet, special relevance can be attributed to strain Berg02-22.2, as these extracts demonstrated anti parasitic and several different anti-cancer activities. Several bioactive capacities of *Gordonia* spp. were referred by [@B51], namely a great antimicrobial capacity of a strain of *G. terrae* isolated from a sponge ([@B15]). Furthermore, [@B51] also reported the various compounds already known to be produced by *Gordonia* genus. These include circumcin A, kurasoin B, soraphinol C; bendigole A, canthxanthin, c-carotene, glycolipids, peptidolipids, and exopolysaccharides. Our work also evidenced the anti-parasitic bioactivity of *Gordonia* sp. Berg02-22.2 against *T. cruzi*. *G. terrae* was isolated from the gut of a *Triatomore* sp. ([@B18]), which is the insect vectors of *T. cruzi* ([@B32]). This actinobacterium along with other bacteria present in the gut microbiota of this insect are believed to play a role in the epidemiology of Chagas disease by competing with *T. cruzi* ([@B18]). Moreover, [@B10] showed that immunized rats with *G. bronchialis* and challenged with *T. cruzi* had a reduction of parasitemia in offspring. The rat's immunological system was activated with increased levels of interferons and reduced levels of interleukins. *Gordonia* is, thus, a genus with an extensive biotechnological value. The dereplication of the extract of *Gordonia* sp. strain Berg02-22.2 points to the presence of both nocardichelin A and B, as well as a novel nocardichelin. Both nocardichelin A and B were first isolated from a strain from the genus *Nocardia* and were shown to strongly inhibit human cell lines from gastric adenocarcinoma, breast carcinoma, and hepatocellular carcinoma ([@B48]). The peptide Gly-Pro-Phe-Pro-Ile was also detected. This peptide is the result of a pancreatic digestion of β-casein and has been described as a competitive inhibitor for cathepsin B which is upregulated in some cancers ([@B30]). The diketopiperazine cyclo(phenylalanylprolyl) was also detected. Furthermore, components with the formulae C~52~H~74~N~10~O~11~, C~35~H~28~N~6~O~8~, C~28~H~41~N~5~O~10~ were detected in the extract but are of an unknown nature.

Species of the genus *Microccocus* produce pigmented colonies which are sources of carotenoid pigments. [@B47] showed that carotenoid pigments produced by *Microccocus roseus* proved to have some antioxidant, antitumor and potent antibacterial activities, in particular against Gram-positive bacteria. *M. luteus* has very few genes associated with secondary metabolism and possesses one of the smallest genomes from the phylum *Actinobacteria*, comprised of a single circular chromosome with 2.5 Mb in size ([@B63]). Bacteria with genome sizes below 3 Mb usually have fewer or none secondary metabolism genes, while above 5 Mb, there appears to exist a linear correlation between genome size and the presence of these genes ([@B12]). This may imply a reduced capacity for the production of bioactive molecules for microorganisms like *M. luteus*. Nevertheless, in both our small-scale and medium-scale extractions, *M. luteus* Berg02-26 proved to produce anti-fungal bioactive molecules and no hepatotoxicity. The dereplication of the extract pointed to the presence of one bioactive diketopiperazine, cyclo(prolyltyrosyl). As discussed above, this diketopiperazine in the form of (3S, 8aS) can have antibacterial and cytoxic effects. Several unidentified molecules were also detected, with compound C~13~H~14~N~2~O~3~ showing a coincidence with caerulomycin G in the DNP. Caerulomycin G is a bypridine alkaloids with a range of activities against *E. coli, Aerobacter aerogenes* and *C. albicans* and cytotoxic activity against the cell lines HL-60, A549 ([@B27]).

The small-scale extracts from *Microbacterium* sp. strain Berg02-79 displayed activity against methicillin-resistant *Staphylococcus aureus* and in the HepG2 cell line. Previous studies had shown activity against *Bacillus subtilis* ([@B16]). Curiously, the methicillin-sensitive strain *Staphylococcus aureus* was not affected by the extract. However, in the medium-scale assay no bioactivity was observed. Once again, the culture conditions may justify this different behavior. *Microbacterium foliorum*, strain \#91_40, showed only hepatotoxic activity in the small-scale screening. Additionally, in the zebrafish fat metabolism assay, the extract from this strain displayed possible anti-lipid accumulation activity. Similarly, *Microbacterium foliorum* strain \#91_29 also displayed this activity. The zebrafish fat metabolism assay was previously used to identify bioactive compounds from marine fungi and plant polyphenols and has the advantage to mirror the complexity of a whole small animal model and to indicate extracts/compounds with physiologically relevant activities ([@B41]; [@B55]). Natural products isolated from different organisms from marine environments were described to have anti-obesity activities ([@B8]). *Microbacterium* strains have already shown to possess a varied and interesting repertoire of bioactive secondary metabolites. Microbacterins A and B isolated from a deep-sea strain of *Microbacterium sediminis*, are peptaibols that showed significant inhibitory effects against human tumor cell lines like HCT-8, Bel-7402, BGC-823, A549, and A2780 ([@B33]). Peptaibols are a class of non-ribosomal linear or cyclic peptides. Additionally, several glycoglycerolipids were isolated from *Microbacterium* sp., and the glycoglycerol GGL.2 showed promising antitumor activities ([@B60]).

As the Duetz extraction requires only a very small volume of culture, a great variety of growth conditions could be tested. From the 10 media used for culturing the *Actinomycetales*, only extracts from 5 media were bioactive but differently for each strain. These five media (AB, CGY, IN-CRY, M016, and R358) all have very different composition. With strain \#91-17, media CGY, IN-CRY, and M016 were the ones that induced more bioactivities. For strain \#91-40 it was medium IN-CRY. Berg02-22.2 and Berg02-78 had better secondary metabolite production in media AB and IN-CRY while Berg02-26 and Berg02-79 the production was favored by media IN-CRY and R358. Remarkably, in the maintenance medium (Marine Broth) no bacterium showed bioactivity. These results give further support to the fact that medium composition is crucial for the activation of the metabolic pathways to produce secondary metabolites. Furthermore, the results obtained illustrated quite well the extended biosynthetic potential of single strains through the "One strain/many compounds" approach ([@B59]).

The dereplication of our extracts revealed the complexity of molecules possibly produced by the bacterial strains. This molecular diversity can justify the various bioactivities (antifungal, anti-cancer, anti-parasitic, and anti-obesity) obtained. Many of the detected molecules likely possess already known bioactivity. This is the case of molecules like nocardichelins, diketopiperazines, and bipyridine alkaloids. Additionally, eight non-identified compounds were also detected. The variety of components encountered proves that the *Actinomycetales* tested are prolific biosynthesizers, reinforcing the bioactive characteristics of this group.
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